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This article features 1999–2008 trends in heart trans-
plantation, as seen in data from the Organ Procure-
ment and Transplantation Network (OPTN) and the
Scientific Registry of Transplant Recipients (SRTR). De-
spite a 32% decline in actively listed candidates over
the decade, there was a 20% increase from 2007 to
2008. There continues to be an increase in listed can-
didates diagnosed with congenital heart disease or re-
transplantation. The proportion of patients listed as
Status 1A and 1B continues to increase, with a de-
crease in Status 2 listings. Waiting list mortality de-
creased from 2000 through 2007, but increased 18%
from 2007 to 2008; despite the increase in waiting list
death rates in 2008, waiting list mortality for Status 1A
and Status 1B continues to decrease. Recipient num-
bers have varied by 10% over the past decade, with
an increased proportion of transplants performed in
infants and patients above 65 years of age. Despite
the increase in Status 1A and Status 1B recipients at
transplant, posttransplant survival has continued to
improve. With the rise in infant candidates for trans-
plantation and their high waiting list mortality, bet-
ter means of supporting infants in need of transplant
and allocation of organs to infant candidates is clearly
needed.
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Introduction
Despite improvements in medical and device therapy for
heart failure, heart transplantation remains the best option
for patients with end-stage heart failure who are deemed
appropriate candidates. Although the incidence and preva-
lence of heart failure are increasing, the number of heart
transplants performed has plateaued [Table 11.4]. In addi-
tion, the number of heart transplants performed per mil-
lion population varied widely from state to state in 2008,
from 0 in several states to >7.8 in nine states (Figure 1)
[Table 11.5]. There are likely many reasons for this vari-
ability (including variable state demographics), but reasons
which must be carefully considered include access to the
waiting list, donor availability, utilization of available donor
hearts, and deaths on the waiting list. Indeed, one of the
program goals for organ allocation by the Organ Procure-
ment and Transplantation Network (OPTN) is to reduce
geographic variations in access to transplantation. Thus, in
this year’s report, where possible, information concerning
geographic variability will be provided. Particular attention
will also be paid to the increasing use of ventricular assist
devices (VADs) in heart transplant candidates. Finally, an
update will be provided concerning the effect of broader
allocation of hearts for Status 1A and 1B candidates (which
went into effect in July 2006) on waiting list mortality and
transplant outcomes.
Heart Waiting List and Recipient
Characteristics
Candidate characteristics
The characteristics of heart transplant candidates are re-
ported for patients actively listed at the end of each calen-
dar year from 1999 to 2008. The number of active candi-
dates declined 32% over the decade, from 2477 to 1684
[Table 11.1a]. Of note, a 20% increase in active candidates
was seen from 2007 to 2008 (1406 and 1684, respectively).
When examined by age, there was a modest increase in
the proportion of pediatric patients on the waiting list (see
‘Pediatric Transplantation’ section for details), as well as
those over 65 years (from 9% to 14%) [Table 11.1a]. The
demographics of the waiting list have changed slightly, with
a decrease in the proportion of white candidates (from
79% to 73%) and an increase in the proportion of both
African American (from 13% to 18%) and Hispanic/Latino
candidates (from 6% to 7%). Candidate gender has shifted
from 21% to 24% female. A small increase in candidates
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Figure 1: 2008 incidence of heart
transplants per 1 million population.
who are recipients of prior solid organ transplants was
seen (from 3% to 7%), mostly in candidates waiting for
heart retransplant (from 3% to 6%). The proportion of can-
didates with congenital heart disease has increased (4% to
9%), and the proportion of candidates with coronary artery
disease has decreased (48% to 40%), with the proportion
of other diagnosis groups remaining similar (currently, pri-
mary cardiomyopathy in 42% and valvular disease in 2%)
[Table 11.1a].
The criteria by which patients are assigned a waiting list
status (1A, 1B and 2) have not changed substantially
since 1999. (See OPTN policies 3.7.3 and 3.7.4 at http://
optn.transplant.hrsa.gov/PoliciesandBylaws2/policies/pdfs
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Figure 2: Status of heart transplant waiting list candidates,
1999–2008.
/policy_9.pdf). There has been a slow but persistent in-
crease in the proportion of Status 1A and 1B patients and
a decline in Status 2 patients over the last several years
(Figure 2) [Table11.1a]. Of patients on the waiting list on
January 1, 2008 (regardless of waiting time accrued), the
following observations can be made: (1) among Status 1A
patients, 16% were ‘downgraded’ to Status 1B and 46%
were transplanted by 60 days. Mortality for those patients
who did not undergo transplantation by 30 and 60 days
was 5% and 7%, respectively. At 365 days, 15 patients
(11%) remained on the waiting list; 4 remained Status
1A, 7 Status 1B and 4 inactive; 18 patients (14%) had
died (6 Status 1A, 2 Status 1B and 10 inactive) (Figure 3).
(2) Among 1B patients, 11% were ‘upgraded’ to 1A, and
25% were transplanted by 60 days. Mortality for Status
Figure 3: Condition of status 1A patients on heart waiting list
as of January 1, 2008, by day.
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Figure 4: Condition of status 1B patients on heart waiting list
as of January 1, 2008, by day.
1B patients who did not undergo transplantation by 30
and 60 days was 1% and 3%, respectively. At 365 days,
94 patients (27%) remained on the waiting list (8 Status
1A, 59 Status 1B, 1 Status 2 and 26 inactive); 24 patients
(7%) had died (5 Status 1A, 7 Status 1B, 1 Status 2 and 11
inactive) (Figure 4). (3) Only 6% of Status 2 patients were
transplanted within 60 days, with a waiting list mortality
of only 1%, although 4% had been upgraded to Status
1A or 1B [Table 11.2b]. At 365 days, 549 patients (59%)
remained on the waiting list (9 Status 1A, 61 Status 1B,
364 Status 2 and 115 inactive); 42 patients (5%) had died
(1 Status 1A, 2 Status 1B, 21 Status 2 and 18 inactive)
(Figure 5). During the last decade, there has been a slight
decrease in the percentage of active patients waiting for 1
year or greater, from 40% in 1999 to 33% in 2008 [Table
11.1a]. The number of inactive patients has remained
relatively high (38% in 2008 vs. 37% in 1999) [Table
11.1b].
Discussion
The increase in Status 1A and 1B and decline in Status
2 patients over the past decade is likely due to increased
utilization of ventricular assist devices (VADs) as a bridge
Figure 5: Condition of status 2 patients on heart waiting list
























k Status 1A Status 1B Status 2
*
*Denotes time point of policy change promoting broader geographic sharing of 
organs for higher status patients
Source: 2009 OPTN/SRTR Annual Report, Table  11.3.
Figure 6: Annual death rates per 1000 patient-years on the
heart waiting list by status, 2001–2008.
to transplant (as detailed in the ‘Patient Care Issues’ sec-
tion of this report). Also, many centers do not actively list
patients who are unlikely to receive an organ offer unless
their clinical status deteriorates to Status 1A or 1B, partic-
ularly since the 2006 implementation of policy promoting
broader sharing. In addition, there is doubt that all patients
who are classified as ‘stable’ Status 2 receive survival ben-
efit from transplantation.
Deaths on the waiting list
The death rate increased from 144 per 1000 patient-years
at risk in 2007 to 170 per 1000 patient-years at risk in 2008
[Table 11.3]. However, the overall death rate of patients
awaiting heart transplantation has decreased over the past
decade, from 199 per 1000 patient-years at risk in 1999
to 170 per 1000 patient-years at risk in 2008. Reduced
death rates over the decade were seen across all adult
age groups and major categories of gender, blood type
(with too few in blood type AB for meaningful analysis)
and race/ethnicity, with the exception of African American
candidates. Death rates also decreased by primary diag-
nosis categories except for congenital heart disease [Table
11.3]. When examined by urgency status, the decline in
waiting list mortality was evident across Status 1A, 1B and
2 patients, although it was most pronounced for patients
listed as Status 1A (Figure 6). Despite this encouraging de-
cline in waiting list mortality overall, the waiting list death
rate varied widely by state in 2008, from 65 in Oklahoma
to 652 in the District of Columbia (among states with ade-
quate cohorts for analysis) (Figure 7) [Table 11.3].
Discussion
The more marked decline in waiting list mortality for Sta-
tus 1A and 1B patients likely reflects the impact of the in-
creased use of left ventricular assist devices (LVADs), and
perhaps, for 2007 and 2008 data, the regional allocation
policy for Status 1A and 1B recipients that began in July
2006. However, the marked variability in waiting list deaths
among states suggests that organs are still not getting to
those who need them most.
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Figure 7: 2008 annual death rates on
heart waiting list.
Recipient characteristics
The number of heart transplants performed in the United
States has varied by 10% over the past decade, from a
low of 2015 in 2004 to a high of 2209 in 2007. While the
number of heart transplants had increased from 2004 to
2007, there was a 2% decrease in 2008 (Figure 8) [Table
11.4]. Over the last 10 years, there was a 12% decrease
in the rate of heart transplants per million U.S. residents,
although this trend appears to have leveled off recently
(Figure 8) [Table 11.5]. Among patients transplanted, there
has been a decrease in transplants in the 50–64 year age
group, with a concomitant rise in transplants performed in
the very young and older patients. The distribution of or-
gans between genders had been quite stable, with a slight
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Source: 2009 OPTN/SRTR Annual Report, Tables  11.4 and 11.5.
Figure 8: Number of heart transplants and incidence of trans-
plant per million population, 1999–2008.
2008. There has been a 17% reduction in the number of
white recipients, with a concomitant rise in transplants per-
formed in the other ethnicity/racial groups. A drop of 26%
was seen in the number of patients transplanted with a
diagnosis of coronary artery disease, while there has been
an increase in the proportion of patients transplanted for
primary cardiomyopathy and congenital heart disease dur-
ing the same period [Table 11.4]. Retransplantation was
the indication for transplantation in 4% of the 2008 co-
hort (see further details in the ‘Retransplantation’ section
of this report). The overall prevalence of heart transplant
recipients has risen 24% from 15 593 in 1999 to 19 308 in
2007 [Table 11.16].
The new status classification system was established be-
tween 1999 and 2008. Within this period, the distribution
of patients among the different status groups at the time
of heart transplantation has shifted toward the more ur-
gent status levels. In 1999, patients transplanted as Status
1, 1A, 1B and 2 accounted for 4%, 34%, 36% and 26%
of transplants respectively. In 2008-–indicative of the new
system and the shift in levels-–the proportions for Sta-
tus 1A, 1B and 2 were 54%, 37% and 9% respectively.
There was a marked increase in Status 1A transplants
and a decrease in Status 2 transplants since broader al-
location for Status 1A and 1B candidates began in July
2006 (Figure 9) [Table 11.4]. In the years before and after
this policy change, the percentage of transplant recipients
with organs having a cold ischemia time less than 180 min
decreased by only 3% (39% in 2005 vs. 36% in 2008).
From 2005 to 2008, the proportion of donor organs with
cold ischemia times over 270 min did not change, and the
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Source: 2009 OPTN/SRTR Annual Report, Table  11.4.
Figure 9: Waiting list status of heart transplant recipients at
transplant, 1999–2008.
increase in the proportion over 180 min was 5% [Table
11.4].
Heart Utilization
At year end 2008, 1684 patients were on the active heart
waiting list, representing a 20% increase in list size from
2007 [Table 11.1a]. While list size increased, the number
of transplants actually decreased by 3% during this same
time period [Table 1.7]. The reported annual death rate
for patients on the heart waiting list in 2008 was 170 per
1000 patient-years at risk, the highest for all organ-specific
categories [Table 1.6].
There were 16 070 deceased organ donors in the United
States during 2007 and 2008 [Table 1.1], and 28% of the
time, a heart was recovered and transplanted. Since so
much variability exists in donor type (standard, extended
criteria and donation after cardiac death), it is imperative
to look at the standard criteria donor (SCD) category when
evaluating heart utilization, as most hearts are recovered
and transplanted from this group. For this analysis, OPO
donor heart utilization was defined as the percent of donor
hearts recovered and eventually transplanted (within or out-
side of the OPO) from SCD donors where at least one
organ (kidney, pancreas, liver, intestine, heart or lung) was
recovered for transplantation. During 2007 and 2008, there
were 10 414 standard criteria organ donors where at least
one organ was recovered for transplant. From this cohort,
a heart was utilized 42% of the time (SRTR analyses, data
as of May 1, 2009).
A review of heart utilization by Organ Procurement Orga-
nization (OPO) donor service area (DSA) during 2007 and
2008 reveals substantial variability. SCD donor heart uti-
lization varied from 11% to 55%. Spearman’s Correlation
Coefficient was used to assess whether there were OPO
donor or other characteristics that correlate with the per-
cent of hearts transplanted. Variables considered included:
race, gender, donor age, cause of death, number of heart
transplant programs in the DSA and number of patients
on the waiting list in the DSA at year end. An increased
number of heart transplant programs and patients on the
waiting list correlated with a trend for increased heart uti-
lization (p = 0.04, p = 0.004 respectively). None of the
other donor characteristics listed above as included in the
analysis were significantly associated with heart utilization.
While a positive correlation exists between percent heart
utilization from SCD donors and the number of transplant
centers in the DSA, the top three OPOs in percent heart
utilization had two or fewer heart centers in their DSA and
still averaged greater than 50% utilization. DSAs with only
two heart centers varied from 24% to 55% utilization, and
those with one center varied from 11% to 53%. Of the
programs with three transplant centers in their DSA, the
range of heart utilization was 33% to 53%. Similar variabil-
ity exists between OPTN regions. With the 2006 alloca-
tion change increasing regional sharing for Status 1A and
1B candidates, one would expect utilization within regions
to be somewhat similar, yet surprisingly, marked variability
still exists (Figure 10).
Discussion
Based on the analysis outlined above, it appears highly
unlikely that donor quality or the number of transplant cen-
ters or heart transplant candidates in a DSA can entirely
explain the wide variability in heart utilization. Best prac-
tices within the DSA community need to be identified and
disseminated in order to optimize heart utilization in all
DSAs to achieve a further decrease in deaths on the heart
waiting list.
Heart Transplant Outcomes
Patient survival, adjusted for age, gender, ethnicity/race
and diagnosis across the entire cohort of patients is 93%,
89%, 75% and 56% at 3 months, 1, 5 and 10 years, re-
spectively [Table 11.12]. Recent-era adjusted patient sur-
vival after heart transplantation at 3 months, 1 year and
5 years posttransplant is similar across the adult range of
patient ages, but there is a marked decrease in survival at
10 years for patients 65 years and older (55%, 59%, 55%
and 46%, for age groups 18–34 years, 35–49 years, 50–
64 years and 65 years and older, respectively) (Figure 11)
[Table 11.12].
At all time points, survival is lower for women than for
men by approximately 2–3% (i.e. 5-year survival for men
transplanted in 2002 or after is 76%, whereas survival for
women in the same era is 73%). In addition, despite similar
3-month survival, medium to long-term survival for African
Americans is lower than in other ethnic/racial groups (10-
year survival is 59% and 43%, respectively, for whites and
African Americans) [Table 11.12]. There is also some diver-
gence in survival based on primary diagnosis. Whereas 1-,
5- and 10-year survival for patients with cardiomyopathy
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Figure 10: Donor utilization—
number of hearts recovered and
transplanted per 100 standard-
criteria donors by donor service area
in 2007–2008.
is 91%, 77% and 59%, the survival for patients with con-
genital disease is 74%, 64% and 53% respectively.
With the exception of donors in the <1 and 1–5 age groups,
recipient survival decreases with each progressively
older donor group. One-year survival among heart recipi-
ents transplanted within 2006–2007 was 96%, 92%, 90%,
86% and 83% among donor age groups 6–11, 12–17, 18–
34, 35–49 and 50–64, respectively. There were not enough
transplants from donors over the age of 65 for a meaning-
ful analysis. Ischemia time also appears to affect patient
survival. Three-month, 1-year and 5-year survival decrease
with increasing cold ischemic time with more pronounced
drops after 270 min; however, 10-year patient survival does
not appear to differ by cold ischemic time. One-year sur-
vival by cold ischemic time among heart recipients trans-
planted in 2006 and 2007 was 92%, 90%, 89%, 84%, 84%
Figure 11: Posttransplant patient survival by age.
and 79% for 0–90, 91–180, 181–270, 271–360, 361–480
and 481+ min, respectively [Table 11.14].
There have been substantial improvements in survival over
time as experience has accrued (i.e. 3-month survival has
improved from 86% to 93% in patients transplanted in
1987 and 2007, respectively, and 10-year survival has im-
proved from 46% to 55% for patients transplanted in 1987
and 1998, respectively) (Figure 12) [Table 11.13]. More re-
cent patients have not yet accrued enough time following
transplantation to determine 10-year survival. In the first
year after heart transplantation, death rates have steadily
decreased, from 191 deaths per 1000 patient-years at risk
in 1999 to 123 deaths per 1000 patient-years at risk in 2007
(Figure 13) [Table 11.7]. For all status groups since 1999
(the year the current status system for allocation was im-
plemented), there has been a decrease in death rates in
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Figure 12: Adjusted short- and long-term survival of heart
recipients, by year of transplant, 1995–2007.
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Source: 2009 OPTN/SRTR Annual Report, Table  11.7.
Figure 13: Annual death rate per 1000 patient-years at risk for
recipients during first year after heart transplantation, 1999–
2007.
the first year after heart transplantation (Figure 14). Impor-
tantly, a trend to a decrease in early posttransplant deaths
for Status 1A recipients was seen between 2005 and
2007, when broader allocation of organs began (although
longer-term follow-up and data from additional recipients is
necessary to confirm this trend) [Table 11.7]. The de-
crease in posttransplant death rates occurred in both
sexes, although females consistently have a modestly
higher death rate. Death rates for whites continue to im-
prove, however this trend is not as apparent in more re-
cent years among other ethnicity/race groups, including
African Americans, Asians, or Hispanic/Latinos (Figure 15)
[Table 11.7].
Patient Care Issues
Ventricular assist devices as a bridge to transplant
Only a tiny fraction of patients with end-stage heart fail-
ure are treated by heart transplantation, despite aggres-
sive organ donor initiatives. In addition, for every five pa-
tients who receive a heart transplant, about one patient
dies on the waiting list (441 deaths on the waiting list vs.
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Figure 14: Annual death rate per 1000 patient-years at risk
during first year after heart transplantation by status, 1999–
2007.
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*Denotes time point of policy change promoting broader 
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Figure 15: Annual death rates per 1000 patient-years during
first year following heart transplantation by race/ethnicity,
1999–2007.
2163 patients transplanted in 2008) [Tables 1.6 and 11.4].
Currently, 68% of heart transplant recipients require life
support (including intravenous medications, mechanical
ventilation, intra-aortic balloon pumps, extracorporeal life
support, total artificial hearts, or VADs) as a bridge to trans-
plant [Table 11.4]. VADs are now routinely used as bridges
to transplant, and increasingly as ‘bridges to decision’ for
patients who may need time and circulatory support while
determination of transplant suitability is established.
The proportion of adult patients undergoing heart trans-
plantation off of a ventricular assist device has risen dra-
matically over the past decade, from 16% in 1999 to 29%
in 2008. The trend has been similar in younger patients,
with 12% of recipients younger than 11 years of age and
20% of adolescents aged 12–17 supported with a VAD in
2008 (Figure 16) (SRTR analyses, data as of May 1, 2009).
The increase in utilization of VADs has led to a few no-
table trends in heart recipient characteristics. Although the
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Source: SRTR analyses, data as of May 1, 2009 
Figure 16: Heart recipients on a VAD at time of transplanta-
tion by age and year, 1999–2008.
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support has remained relatively stable, the proportion
transplanted from a nonhospital setting has increased from
39% to 48%, representing primarily ambulatory, out-of-
hospital VAD-supported patients [Table 11.4]. To place this
in perspective, between July 2006 and July 2008, the pro-
portion of patients with a VAD at the time of listing was
13%, while the proportion of patients with a VAD ever
while listed was 20% (1).
Discussion
Evidence in support of VAD use in heart transplant candi-
dates is largely observational, demonstrating reduced mor-
tality with VAD use in inotrope-dependent heart transplant
candidates and derived from a study of VAD use as destina-
tion therapy (2). However, as VAD utilization has increased,
concerns have been raised about the effect on posttrans-
plant outcomes. An OPTN report found a higher mortality in
VAD-supported patients when compared to non-VAD Sta-
tus 1 patients (3) at 6 months and 5 years after transplant.
Although these findings were adjusted for risk factors at
the time of transplant, important differences at the time of
VAD insertion were not addressed. In particular, many pa-
tients receive VADs as a ‘bridge to candidacy’ in the hopes
of improving end organ function, pulmonary vascular resis-
tance, or medical compliance. In addition, this report is now
largely historical, since it included early, first-generation de-
vices less frequently used today. A more recent report from
a single center (4), and an abstract presented at the Ameri-
can Transplant Congress in 2009 using the OPTN database
(5), have shown equivalent early posttransplant outcomes
whether or not patients received a VAD as a bridge to
transplant.
Shortcomings in first-generation VADs (volume displace-
ment, pulsatile pumps) have led to development of en-
hanced designs, with the goal of improved durability
(longer possible support times) and fewer complications.
A clinical trial of the HeartMate II LVAD demonstrated im-
proved quality of life and functional status in a group of
patients supported using the device as a bridge to trans-
plant (6). This technology has recently gained U.S. Food
and Drug Administration (FDA) approval for bridge to trans-
plantation.
Ventricular assist technology is in rapid evolution and may
provide a realistic alternative to transplantation in the fu-
ture. However, it has been difficult to integrate VAD use
as a bridge to transplant in heart transplant allocation pol-
icy because of the paucity of information prospectively
collected for the OPTN database; rapidly changing tech-
nology and outcomes compound this difficulty. Additional
data from other sources, such as the Interagency Reg-
istry for Mechanical Assisted Circulatory Support (INTER-
MACS), will add to our future knowledge base, and may
take us closer to an allocation method similar to the Lung
Allocation Score, which defines organ allocation based on
risk of death without transplant and expected survival if
transplanted. In the not-too-distant future, improved VAD
outcomes may lead to a lower priority for VAD-supported
patients and a higher priority for patients with other dis-
eases, such as restrictive, congenital, or hypertrophic
cardiomyopathy, or patients with electrical or coronary
instability.
Immunosuppression for heart transplant recipients
Immunosuppression for heart transplant recipients has
continued to evolve over the past decade. Induction ther-
apy, primarily in the form of equine antithymocyte glob-
ulin (Atgam
R©
) or muromonab-CD3 (OKT3
R©
), was used
for 34% of patients in 1999, increasing to 52% in
2008, although the drugs used have shifted toward rabbit
anti-lymphocyte globulin (Thymoglobulin
R©
) in 18%, or
monoclonal antibody therapy directed against the IL-2 re-
ceptor [daclizumab (Zenapax
R©
) or basiliximab (Simulect
R©
)]
in 25% of heart recipients [Table 11.6a].
The overwhelming majority of transplant recipients
continue to be discharged on triple drug therapy
consisting of a calcineurin antagonist, mycophenolate
mofetil/mycophenolic acid or other antimetabolite, and
steroids. In 2008, the most common discharge regimen, by
far, was tacrolimus, mycophenolate mofetil/mycophenolic
acid and steroids (58% of transplant recipients) [Table
11.6d]. The use of the mammalian target of rapamycin





) at discharge, in various combinations with
other agents, is only 3%, likely out of concern for impaired
wound healing in the immediate postoperative period
[Table 11.6e].
At 1 year following transplantation, triple drug ther-
apy with tacrolimus, mycophenolate mofetil/mycophenolic
acid and steroids remains the predominant treat-
ment regimen (approximately 37% of heart recipients)
[Table 11.6f]. Tacrolimus use in any combination is now
68%, while cyclosporine use is only 27%. Mycopheno-
late mofetil/mycophenolic acid is the most common an-
timetabolite, utilized in 80% of patients. Since 1998, there
has been a small but important trend toward steroid-free
drug regimens by 1 year following transplantation (38% of
2007 recipients). The use of either sirolimus or everolimus
between discharge and 1-year posttransplant is approxi-
mately 10%, reflecting the fact that mTOR inhibitors may
have utility in preventing and/or retarding transplant coro-
nary artery disease [Table 11.6g].
A declining number of recipients have received treatment
for rejection during the first year following transplanta-
tion (19% in 2007 compared with 42% in 1998). The
overwhelming majority of rejection episodes are treated
with steroids (90%), while approximately 17% are treated
with antibody therapy, most frequently with rabbit anti-
lymphocyte globulin [Table 11.6i].
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Pediatric Transplantation
Pediatric heart transplant candidates and recipients (<18
years of age) represent a distinct population in comparison
with adults. Important differences exist in etiologies of
organ failure, the need for more complex and techni-
cally challenging surgical procedures, developmental ef-
fects on pharmacokinetic properties of immunosuppres-
sive agents, immunological aspects of transplantation in
the developing immune system and susceptibility to cer-
tain posttransplant complications, most notably infectious
diseases and lymphoproliferative disorders. This section
focuses on pediatric heart transplantation, drawing atten-
tion to differences from adult candidates and recipients.
Candidate characteristics
The number of pediatric patients awaiting heart transplan-
tation has been relatively steady over the past 10 years,
with 122 actively awaiting transplantation at the end of
2008 [Table 11.1a]. Although the absolute number of pe-
diatric candidates on the active waiting list did not change
over the last decade, there has been a modest rise in the
total proportion of active candidates that are less than 18
years of age, rising from 5% at the end of 1999 to 7% at
the end of 2008. The number waiting was similar for age
groups < 1 year (n = 30), 1–5 years (n = 27), 6–11 years
(n = 27) and 12–17 years (n = 38). However, for any single
12-month age group, infants (0–1 year of age) make up,
by far, the largest group of candidates. Infants (<1 year)
represented 40% (223 of 558) of all new pediatric regis-
trations in 2008 (SRTR analyses, data as of May 1, 2009)
[Table 15.3].
The diagnoses leading to listing for transplantation vary
by age. For infant candidates, the indication for placement
on the waiting list is a congenital heart anomaly in 65%
of patients (SRTR analyses, data as of May 1, 2009). In
older children and adolescents, cardiomyopathy is the lead-
ing indication for transplantation; however, congenital car-
diac anomalies continue to account for a substantial mi-
nority of transplants (30% in the 12–17 year age group).
These observations are important because complex car-
diac anatomy and small size add to the risks and complexity
of VAD support in very young children. Difficulty support-
ing young patients with complex congenital heart disease
undoubtedly contributes to their high waiting list mortality
(see below).
Analysis of waiting list status reveals a steady rise in the
proportion of candidates who are listed as Status 1A at the
time of listing. In 2008, 83% of infants, 65% of patients
age 1–5, 62% of patients age 6–11 and 58% of adolescents
were listed as Status 1A (SRTR analyses, data as of May
1, 2009). Thus, initial listing as Status 1A is more common
in younger candidates, especially infants.
Deaths on the waiting list
Waiting list mortality for pediatric heart transplant candi-
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Figure 17: Annual death rate for pediatric candidates (<18
years) by status on the heart waiting list.
cur in Status 1A patients, with very low 1-year mortality
for Status 2 patients (Figure 17) (SRTR analyses, data as
of May 1, 2009). Infants have the highest waiting list mor-
tality of any age group (adult or pediatric) (Figure 18) [Table
11.3]. The annual death rate was 1361 per 1000 patient-
years at risk for infants in 2008, compared to 170 for all age
groups combined (adult and pediatric). The second highest
waiting list annual death rate (among all age groups, pedi-
atric and adult) was for the 1- to 5-year age group at 442
per 1000 patient-years at risk. For children above 6 years of
age, the waiting list death rates are broadly comparable to
those for adults. In general, there has been no important
change in annual death rates over the last decade among
pediatric candidates, except for in the 12- to 17-year age
group, which has seen a fall in annual death rate on the
waiting list from 372 per 1000 patient-years at risk in 1999
to 180 in 2008. It seems likely that this reflects the in-
creasingly successful use of VADs to support critically sick
adolescents to transplantation over the last decade.
Recipient characteristics
Over the past 10 years, children have accounted for an in-
creasing percentage of all heart transplants (12% in 1999,
17% in 2008) [Table 11.4]. There has been a steady in-
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Source: 2009 OPTN/SRTR Annual Report, Table  11.3.
Figure 18: 2008 wait list mortality by age.
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Figure 19: Posttransplant patient survival by age.
1999 to 366 in 2008. The largest increase has occurred in
children less than 6 years of age. The rate of transplantation
per 1 million population remains higher for infants than for
any other age group, at 23 [Table 11.5]. For all other pe-
diatric age groups, the rates were generally less than for
adults and ranged from 3 to 5 per million population. The
high rate of transplantation in these very young children
reflects the incidence of severe symptomatic congenital
heart disease in the first year of life, as well as the relatively
high incidence of cardiomyopathy in this age group. At the
time of transplantation, 96% of infants, 76% of those age
1–5, 80% of those aged 6–11 and 78% of adolescents
were Status 1A (SRTR analyses, data as of May 1, 2009).
As with initial wait-listing status, infants were most likely
to be Status 1A at the time of transplantation compared
with the other pediatric age groups.
Heart transplant outcomes
Death rates per 1000 patient-years at risk during the first
year after transplantation for 1999–2007 were generally
highest for the infant age group compared with all other
age groups (adult and pediatric), while rates were gener-
ally lower for most other pediatric age groups. The infant
annual death rate for 2007 recipients was 230 deaths per
1000 patient-years at risk compared with 123 for all age
groups combined [Table 11.7]. Rates for the pediatric age
groups 1–5 years, 6–11 years and 12–17 years were 85,
35 and 60 deaths per 1000 patient-years at risk, respec-
tively. Importantly, there is no evidence of a reduction of
first-year annual death rates among infant heart recipients
over time, but reductions have been observed for all other
pediatric age groups.
Adjusted patient survival assessed through time-to-event
analyses reveals trends different from adults. The lowest
3-month and 1-year survival rates among all groups (includ-
ing adults) is for recipients less than 1 year of age (86% and
79% respectively) (Figure 19) [Table 11.12], likely related
to the technical challenges posed in surgical procedures
for these very young patients, many of whom have com-
plex congenital heart disease. Interestingly, these same
recipients have among the highest 10-year survival (66%),
likely related to the immaturity of the immune system in
infancy and the reduced prevalence of posttransplant coro-
nary artery disease (Figure 19). Beyond infancy, short-term
survival is excellent in all other pediatric age groups, with 1-
year survival exceeding that for all adult age groups (1-year
survival of 92–96% among pediatric recipients from 1–17
years compared with 1-year survival of 85–89% among
adult recipients of various age groups) [Table 11.12]. Of
interest, the 1–11 year age groups maintain late graft sur-
vival rates distinctly superior to those of adults (about 10%
higher), while recipients in the 12- to 17-year age group
have late graft outcomes worse than all other age groups
(10-year survival 46%), with the exception of the over 65
year-old population (10-year survival 45%) (Figure 19) [Table
11.8]. It is widely speculated that these poor outcomes in
adolescent recipients reflect nonadherence to their medi-
cal regimens.
Ventricular assist device use in children
It has been possible to support most adolescent candi-
dates with adult VADs, most commonly with pneumatic
devices in a paracorporeal configuration, and the number of
children receiving VADs in the 12- to 17-year age group has
been relatively stable over the last 10 years. In 2008, 20%
of 12–17 year-olds were supported with a VAD at the time
of transplant (Figure 16) (SRTR analyses, data as of May
1, 2009). Results in this age group have been encouraging
when the underlying diagnosis is cardiomyopathy rather
than congenital heart disease (7). The age group with the
fastest-growing use of VADs is the under 12-year-old pop-
ulation, where 1% to 5% of recipients were supported
with a VAD in 1999 to 2004, compared with 12% of heart
recipients in 2008. This trend is likely the direct effect of
availability of devices designed for pediatric use and made
available through ‘compassionate use’ protocols. Most pro-
grams have supported children under 25 kg with the Berlin
Heart (EXCOR
R©
, Berlin Heart GmbH, Berlin, Germany),
which has been developed in various sizes. Future reports
will evaluate the efficacy of pediatric VADs as a bridge to
transplantation in small children, including infants. Encour-
agingly, a number of new VADs designed specifically for
pediatric use are under development, supported by a con-
tract from the National Heart, Lung and Blood Institute of
the National Institutes of Health (8).
ABO-incompatible heart transplants in infants
A unique feature of pediatric transplantation is the grow-
ing use of ABO-incompatible heart transplantation (ABO-I)
among infants. The percentage of eligible infants listed
for an ABO-I heart increased from 0% before 2002 to
over 50% in 2007. The strategy was developed by West
and colleagues in Toronto, and relies on the observation
that isohemagglutinins (anti-A and anti-B antibodies) gen-
erally develop late in infancy (9). When transplantation is
performed prior to the natural development of antibodies
against blood groups antigens, B cell tolerance appears to
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develop, and antibodies are usually not produced during
long-term follow-up. International outcomes to date sug-
gest no differences in adjusted posttransplant survival be-
tween infants receiving compatible versus incompatible
blood group heart transplants (10). It was hoped that intro-
duction of this program in the United States would result
in reduced waiting list time and decreased pretransplant
infant mortality without an increase in posttransplant mor-
tality. However, at the present time, OPTN policy allocates
ABO-I hearts to infant candidates only after all attempts to
place the organ with an ABO-compatible candidate have
failed. Therefore, most infants eligible to receive ABO-I
organs continue to receive compatible organs (or die on
the waiting list). There is no evidence at this time that the
policy of allowing listing for an ABO-I organ has led to a
fall in infant waiting list mortality in the United States. If
ongoing analyses of posttransplant outcomes continue to
reveal no difference in survival between ABO-I and ABO-
compatible transplants, then current OPTN policy will need
to be reviewed to determine if equal preference should be
given to candidates listed for ABO-I and ABO-compatible
transplants. New OPTN policy also intends to allow ABO-I
transplants to be offered to young children between 1 and
2 years of age if they demonstrate absent or a very low
titer of the relevant isohemagglutinins.
Retransplantation
As indicated previously, the prevalence of people living
with a functioning heart transplant has increased from
15 593 at the end of 1999 to 19 308 at the end of 2007
[Table 11.16]. Therefore, there are more heart recipients
who might ultimately be candidates for retransplantation
at later times following transplantation when outcomes are
better than when retransplantation is performed for acute
rejection or early allograft failure (11,12). This trend is in-
deed shown in the data available. From 1999 to 2008, a
time when the number of active candidates waiting for
transplant has declined, the percent of active candidates
with retransplantation as the primary diagnosis has steadily
increased from 2% to 6% (Figure 20) [Table 11.1 a]. The
death rate for candidates for retransplantation has varied
over the past decade, but for 2008 was 221 deaths per
1000 patient-years [Table 11.3], representing the highest
waiting list death rate for any known primary diagnosis cat-
egory except for candidates with congenital heart disease.
This death rate on the waiting list is consistent with the
fact that, although the percentage of patients listed with
the indication of retransplantation has increased over the
last decade, the percent of transplant recipients that are
retransplants has been stable (4% in 1999 and in 2008)
(Figure 20) [Table 11.4]. Following retransplantation, 3-
month, 1-year, 5-year and 10-year unadjusted graft survival
remains inferior to that of all transplant recipients (90%,
84%, 65% and 42% for retransplants vs. 93%, 88%,
74% and 55% respectively) [Table 11.10]. The high rate
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Source: 2009 OPTN/SRTR Annual Report, Tables  11.1a. and 11.4
Figure 20: Heart candidates and heart recipients with prior
heart/heart–lung transplant.
plantation is concerning. However, the outcomes for re-
transplantation remain inferior to those following primary
transplantation. Any attempts to allocate more organs to
candidates for retransplantation would diminish the over-
all life-years that could potentially be saved by allocation
of those donor hearts to de novo recipients. Ongoing ef-
forts by the heart transplant community to select the best
candidates for retransplantation are clearly needed.
Heart–Lung Transplantation
Surgical and medical therapies have improved for many
of the diseases that have traditionally been treated with
heart–lung transplantation. Examples of this include more
sophisticated surgical options for patients with congenital
heart disease, a rise in the number of patients with pul-
monary arterial hypertension (PAH) treated with lung (sin-
gle and/or bilateral) transplantation alone, and the larger
spectrum of medications (oral, inhaled and intravenous),
used for patients with PAH. Because of this, the practice
of heart–lung transplantation continues to decrease in the
United States and worldwide.
The wait-list characteristics at the end of 2008 demon-
strated that a broad spectrum of disease was represented
amongst candidates for heart–lung transplantation. Of the
33 candidates actively listed at that time (6 pediatric, 27
adult) [Table 13.1a], the most common diagnoses were the
Eisenmenger syndrome spectrum of diseases (55%) and
the idiopathic pulmonary arterial hypertension spectrum of
diseases (15%). Mixed diseases (such as a combination of
coronary artery disease and idiopathic pulmonary fibrosis,
or valvular heart disease and COPD) accounted for 14% of
candidates.
The number of heart–lung transplant recipients in the
United States has declined from 51 in 1999 to 27 in 2008
[Table 13.4]. For those who underwent heart–lung trans-
plant in the years of 2007–2008, (58 total), 33% carried
the diagnosis of the Eisenmenger syndrome spectrum of
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diseases and 24% the idiopathic pulmonary arterial hy-
pertension spectrum of diseases. Patients with primary
cardiac lesions with secondary pulmonary hypertension
represented 7% of cases.
Heart–lung recipient survival has generally been less than
that of many other forms of transplantation. Approximate
adjusted survival rates are 86% at 3 months, 81% at 1
year, 45% at 5 years and 29% at 10 years [Table 13.12].
These rates more closely approximate the survival rates of
lung-only transplant recipients than heart-only recipients,
suggesting that the biology of survival is dictated more
by the presence of bronchiolitis obliterans syndrome than
by transplant coronary artery disease. Because of this, a
more comprehensive discussion of heart–lung transplan-
tation can be found in the chapter entitled: ‘Lung Trans-
plantation in the United States, 1999–2008’.
Summary
This review of heart transplantation over the past decade
has revealed successes (i.e. a decrease in waiting list
deaths, especially for Status 1A candidates, and a con-
tinued improvement in posttransplant survival), but also
presents us with new challenges. The disparities in trans-
plants per million population, deaths on the waiting list and
donor heart utilization among OPOs are clearly worthy of
further study. In addition, with the increased percentage of
patients on VADs at the time of transplant, more detailed
data concerning patients on VADs while listed and at trans-
plant are needed to develop a heart allocation policy that
goes beyond status to better reflect waiting list mortal-
ity and posttransplant benefit. The increased percentage
of infants on the waiting list and their high waiting list
mortality also challenges us to develop improved methods
of bridging infants to transplantation and allocating donor
hearts to infants. Only ongoing careful data collection and
analysis can help further improve heart allocation policy in
such a way as to benefit those most in need while remain-
ing good stewards of a scarce and precious resource, the
donor heart.
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